Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
about
Management of bleeding and coagulopathy following major trauma: an updated European guideline.Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceReversal of oral anticoagulationAnticoagulation drug therapy: a reviewSpotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatranGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismThe Reversal of Direct Oral Anticoagulants in Animal Models.Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Diagnosis and Management of Acute Intracerebral Hemorrhage.Trends in the development of oral anticoagulants.Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyEdoxaban: an update on the new oral direct factor Xa inhibitor.Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.Management of acute stroke in patients taking novel oral anticoagulants.Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.Treatment options for venous thromboembolism: lessons learnt from clinical trials.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012Emergency reversal of dabigatran for emergency surgery.Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.Positive outcome after intentional overdose of dabigatran.Coagulation assessment with the new generation of oral anticoagulants.Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studiesThe perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Perioperative management of coagulation in nontraumatic intracerebral hemorrhageReversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human bloodA new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarinEx vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.Rivaroxaban and hemostasis in emergency care.Current state of anticoagulants to treat deep venous thrombosis.The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.Anticoagulants in atrial fibrillation patients with chronic kidney disease.Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.
P2860
Q21092902-B63A4DFE-CD15-4009-A080-893B98CAE336Q26782483-BA437270-1E0F-43DD-9B04-D49DC041851FQ26827835-4B4C411C-D268-4714-A7FB-1E88710BE064Q27021871-E35A6D52-DCDD-4810-927D-62C0B2FA5C39Q28066262-FF8D2CDD-0CDE-43EF-A395-B1BDA1DE98E7Q28076077-5368FF68-7AA0-4968-8890-61B0469EDEAFQ28087447-FC08D891-0633-47A4-88F3-051E0737F4B3Q30491580-121D9CFE-4465-4F33-B0B3-F3A7E7ADC4FCQ30595943-48A5E8BA-ACE9-4423-A7ED-032FA328A674Q31136660-6FB5C7E8-BB2A-4E09-B5B6-56515DE78E9EQ33424198-EA626C6F-23D4-4549-9B9E-C49E7798EDD4Q33556350-DF9CC4FE-351D-4436-B207-615915E0BB84Q33581189-3582DFB0-C132-419A-9292-D5CFCC17079DQ33854667-13BE8D2B-52C7-4087-BC50-F1EE36E97787Q33891915-482165F2-A4D8-48E1-9761-A7A7AC8E78FFQ33935409-1DF7FDAA-C755-41AC-9518-EDB90465743AQ33936087-A7EBECE0-69ED-4C19-836C-68C934ED6A04Q34111320-DA9255D6-2A9D-40E5-9EE4-6A56BF78DBC8Q34497406-A096FAE9-B247-4429-B30F-04EC94240C8FQ34694544-546A96A2-FAD8-45C1-86DF-08D79195A9D3Q34725585-473C6FF4-B2CC-44FB-B286-06CB712EE0B7Q35578443-BAAFCE13-6EA8-4535-9F45-DE40A255AAFDQ36515685-0531CB53-09E7-4E1F-8B6C-C1EF68BBBFFFQ36852294-AA20A3F7-7876-4FAD-9E33-CF89F1082DF5Q36968781-CE094AF5-5C89-4D27-93C6-EA7E048DB145Q36984232-66C1B54D-47C3-4E88-A500-68BB125382D1Q37194881-1E9A2E27-0539-4352-AE47-FC60390527FBQ37251490-B6554859-0011-4E06-ADC7-5AA7966A289DQ37274433-6A88537D-7A4D-4A2F-B12E-E4AC3DC6379FQ37297475-BB156DD6-0EF3-4AAE-8732-B7BA16E4867FQ37312021-BCFF7D24-0B69-40E0-8BF6-DBB2E4D72C10Q37388007-70FC0E5A-AAA5-4F0C-9E9E-A6616900E5BAQ37631564-11555FF5-45EA-4DBC-97C6-F5F88704AEA3Q37638073-6DAE4CAB-6A45-40EB-87C0-0042C72E197CQ37655400-C5773896-42A8-483D-A148-1F020E223040Q37669387-817334DE-A027-40FC-864B-55E7D5020BC8Q37731832-B3E3D30D-ECCD-499F-A0E1-7EB2C8125D4BQ38017613-8812E7CB-9F38-4F54-B947-E51892CE8954Q38028855-70110BAA-380B-471E-99CC-34ECECE2AD8CQ38049617-8D406ACA-0BAA-4B98-A7B9-800876B5ABD6
P2860
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@en
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@nl
type
label
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@en
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@nl
prefLabel
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@en
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@nl
P2093
P2860
P356
P1476
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
@en
P2093
Alex C Spyropolous
Andra James
Anthony K C Chan
David A Garcia
Elizabeth M Van Cott
Jack Ansell
Jim D Douketis
Mark Crowther
Peter A Kouides
Scott Kaatz
P2860
P304
P356
10.1002/AJH.23202
P478
87 Suppl 1
P577
2012-04-04T00:00:00Z